Beaumont Study Finds ControlRad Cut Radiation Exposure to Electrophysiology Staff and Patients by More than Half

Beaumont Hospital’s Dr. Nishaki Mehta announced impressive data for the ControlRad technology on April 29th at the Heart Rhythm Society Annual Meeting.

The results of Beaumont Health’s prospective and randomized study were presented in San Francisco at the largest educational gathering of cardiologists specializing in cardiac pacing and electrophysiology in the world.

The study found a 60% and 77% decrease in radiation exposure to the physician’s (closest to the X-ray source) and the surgical tech’s thyroid badges, respectively, during procedures using ControlRad. The study also revealed a 53% radiation reduction in dose area product (DAP), representing radiation to the patient.1

The study, which enrolled 90 cardiac device implant procedures, concluded that the ControlRad technology reduces radiation exposure not only to the operators but also to the patients during electrophysiology procedures.

“The ControlRad technology seamlessly integrates into our workflow and offers the promise of radiation reduction to everyone in the lab. It is another powerful tool to add to our armamentarium as we protect our colleagues and patients,” said Dr. Mehta, primary investigator and presenter on the REDEFINE-EP study. “While we have moved away from radiation use in ablations, it is unfortunately an important part of our device implantation, device extractions and left atrial appendage occlusion device procedures.”

Beaumont Hospital Royal Oak is the largest health system in Michigan and ranked one of the best in the nation for cardiology and heart surgery by U.S. News and World Report.

The FDA-cleared ControlRad Select is commercially available and retrofits on facilities’ existing Siemens imaging systems.

1 REDEFINE: A Prospective, Randomized Evaluation of the ControlRad System to Reduce Radiation Exposure During Cardiac Implantable Electronic Device Procedures; Nishaki Mehta, MD; HRS 2022.

 

About ControlRad

ControlRad is a privately held medical technology company developing innovative products that dramatically reduce the radiation exposure from fluoroscopically guided procedures (FGP) for patients and healthcare professionals. ControlRad’s products are designed to improve safety without compromising image quality or workflow. They include an integrated set of proprietary components, which optimize the X-ray beam to deliver optimal image quality in the clinically relevant region while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Atlanta, Georgia and has engineering development facilities in Kfar Saba, Israel. For more information, visit www.controlrad.com.